<DOC>
	<DOCNO>NCT02831634</DOCNO>
	<brief_summary>Feasibility study method allow identification tumor mutate epitopes patient breast cancer cutaneous melanoma , quantification CD8+ T cell specific tumor neo-antigens lymph node</brief_summary>
	<brief_title>A Feasibility Study Identify T-cell Responses Neo-epitopes Tumor Invaded Lymph Nodes ( NeoEpitope )</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Patients 18 year Patient HR+ , HER2 nodepositive ( proven cytology ) invasive ductal carcinoma breast cancer , grade ( SBR ) II III , axillary dissection program , Or patient cutaneous melanoma schedule lymph node dissection Institut Curie include dissection lymph node drain tumor , Voluntary sign date write informed consent prior specific study procedure , Patients treat breast cancer receive neoadjuvant chemotherapy Patients treat breast cancer distant metastasis ( M+ ) â€¢ Only patient breast cancer : oral systemic corticosteroid treatment receive within 30 day prior surgery Patients immunosuppressive treatment diagnose immunodeficiency Patients know chronic viral infection HIV1 2 , HBV , HCV Patients cancer diagnose within 5 year ( except squamous cell cutaneous carcinoma ) Patients without French social security Patients deprive liberty place authority tutor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>cutaneous melanoma</keyword>
</DOC>